Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stada Saga Set To End As Board Backs Bain And Cinven Bid

Executive Summary

The equity firms finally look like getting their hands on the German generics group as Stada urges shareholders to back the €4.1bn deal and only 63% need to support it.

You may also be interested in...

Deal Watch: Valeant Continues Divestment Spree By Selling Obagi At A Loss

Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.

Try, Try Again: Bain And Cinven File Fresh Bid For Stada

Stada is likely to approve a second takeover bid from equity groups Bain and Cinven soon, at a new price of €66.25 per share; an offer cleared by Germany's stock market authorities despite a ban in the country on repeat acquisition bids within 12 months.

What Now For Lonely Stada? Bain & Cinven Takeover Bid Collapses

In a surprising twist, Stada investors have not rallied behind a €5.3bn takeover bid from equity groups Bain and Cinven; analysts are baffled as to why the deal didn’t win enough support and what Stada's shareholders are hoping for now.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts